Ruboxistaurin
![]() | |
![]() | |
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
CAS Number |
169939-94-0 ![]() |
PubChem (CID) | 153999 |
IUPHAR/BPS | 5263 |
ChemSpider |
135727 ![]() |
UNII |
721809WQCP ![]() |
ChEMBL |
CHEMBL91829 ![]() |
Chemical and physical data | |
Formula | C28H28N4O3 |
Molar mass | 468.546 g/mol |
| |
![]() ![]() |
Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
On February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin,[1] with a request for an additional clinical trial, which would take 5 years to complete.[2]
Mechanism of action
Ruboxistaurin is an inhibitor of protein kinase C-beta.[3]
References
- ↑ "Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant". Retrieved 2008-02-15.
- ↑ "Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy". Retrieved 2008-02-15.
- ↑ Clarke M, Dodson PM (December 2007). "PKC inhibition and diabetic microvascular complications". Best Pract Res Clin Endocrinol Metab. 21 (4): 573–86. doi:10.1016/j.beem.2007.09.007. PMID 18054736.
External links
This article is issued from Wikipedia - version of the 9/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.